05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
Dividend recapitalization activity plunged in the immediate aftermath of COVID-19 but, as markets re...
Read More >
Selling your company for a huge profit sounds enticing. What could be wrong with getting a huge up-f...
Read More >
The non-ERISA §403(b) space is the last bastion of high, hidden costs in retirement plans. That’s t...
Read More >
On June 19, 2019, the New York State Legislature passed Senate Bill S.6577, which upon Governor Cuom...
Read More >
The COVID-19 pandemic has caused more than just health concerns for our community—it has also creat...
Read More >
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent deci...
Read More >